Cordlife Group Limited
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic tes… Read more
Cordlife Group Limited - Asset Resilience Ratio
Cordlife Group Limited (CLIFF) has an Asset Resilience Ratio of 9.43% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Cordlife Group Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cordlife Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.54 Million | 9.43% |
| Total Liquid Assets | $19.54 Million | 9.43% |
Asset Resilience Insights
- Limited Liquidity: Cordlife Group Limited maintains only 9.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cordlife Group Limited Industry Peers by Asset Resilience Ratio
Compare Cordlife Group Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Cordlife Group Limited (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Cordlife Group Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 22.60% | $49.08 Million | $217.14 Million | +2.21pp |
| 2023-12-31 | 20.39% | $46.59 Million | $228.46 Million | -2.32pp |
| 2022-12-31 | 22.71% | $51.79 Million | $228.00 Million | +1.68pp |
| 2021-12-31 | 21.04% | $36.44 Million | $173.20 Million | +5.63pp |
| 2020-12-31 | 15.41% | $27.19 Million | $176.46 Million | +5.20pp |
| 2019-12-31 | 10.21% | $17.03 Million | $166.79 Million | -5.00pp |
| 2018-12-31 | 15.21% | $32.36 Million | $212.69 Million | +1.94pp |
| 2017-12-31 | 13.28% | $28.97 Million | $218.24 Million | -3.85pp |
| 2016-12-31 | 17.13% | $34.04 Million | $198.73 Million | -8.14pp |
| 2015-12-31 | 25.27% | $68.37 Million | $270.57 Million | +21.22pp |
| 2014-12-31 | 4.05% | $10.02 Million | $247.28 Million | -2.64pp |
| 2013-12-31 | 6.69% | $12.77 Million | $190.71 Million | +6.41pp |
| 2012-12-31 | 0.28% | $342.00K | $120.45 Million | -- |